FY2025 · ended Dec 31, 2025 · Revenue $2.25B, +6.7% YoY · Filed Feb 26, 2026
Enovis Corp (ENOV) files with the SEC under industry code 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.2 billion and a net loss of $1.2 billion. Free cash flow was $19.9 million. As of Oct 2, 2026 it held $13.0 million in cash and investments and $1.3 billion in total debt.
Revenue (TTM)
$2.31B
+3.3% vs year-ago TTM
Net income (TTM)
$-527.40M
+61.4% vs year-ago TTM
Operating cash flow (TTM)
$259.02M
+19.3% vs year-ago TTM
Free cash flow (TTM)
$69.56M
+205.6% vs year-ago TTM
EPS (TTM)
$-9.18
+61.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
57.25M
+0.5% vs prior year
Net cash
$-1.27B
as of Oct 2, 2026
Operating margin
-20.6%
FY 2026
Company profile
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
- Listed as
- ENOV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lewisville, TX
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1420800
- Former names
- Colfax CORP (until Mar 18, 2022)
Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
- Intuitive Surgical Inc ISRG
- Edwards Lifesciences Corp EW
- STERIS plc STE
- Zimmer Biomet Holdings, Inc. ZBH
- Smith & Nephew PLC SNN
- Align Technology Inc ALGN
- MSA Safety Inc MSA
- Establishment Labs Holdings Inc. ESTA
All 29 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.2B | $2.1B | $1.7B | $1.6B | $1.4B |
| Operating income | -$1.1B | -$775.7M | -$65.7M | -$71.2M | -$62.8M |
| Net income | -$1.2B | -$825.5M | -$33.3M | -$13.3M | $71.7M |
| Diluted EPS | -$20.75 | -$14.93 | -$0.61 | -$0.25 | $1.40 |
| Operating cash flow | $217.3M | $113.5M | $135.0M | -$55.9M | $356.1M |
| Free cash flow | $19.9M | -$67.2M | $12.8M | -$161.3M | $251.9M |
| Total assets | $3.8B | $4.7B | $4.5B | $4.3B | $8.5B |
| Total liabilities | $2.3B | $2.2B | $1.1B | $823.4M | $3.9B |
| Stockholders' equity | $1.5B | $2.6B | $3.4B | $3.4B | $4.6B |
| Cash and investments | $36.4M | $48.2M | $36.2M | $24.3M | $680.3M |
| Total debt | $1.4B | $1.4B | $532.4M | $328.7M | $2.3B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 1, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 19, 2026 | May 19, 2026 |
All 1005 Enovis Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.